Published in J Virol on July 01, 1994
Benchmarking B cell epitope prediction: underperformance of existing methods. Protein Sci (2004) 2.70
Identification of a conserved B-cell epitope on reticuloendotheliosis virus envelope protein by screening a phage-displayed random peptide library. PLoS One (2012) 1.01
Peptide vaccine against canine parvovirus: identification of two neutralization subsites in the N terminus of VP2 and optimization of the amino acid sequence. J Virol (1995) 1.00
Peptide Vaccine: Progress and Challenges. Vaccines (Basel) (2014) 0.94
Chloroplast-derived vaccine antigens and biopharmaceuticals: expression, folding, assembly and functionality. Curr Top Microbiol Immunol (2009) 0.94
Identification of domains in canine parvovirus VP2 essential for the assembly of virus-like particles. J Virol (1996) 0.83
Truncated forms of viral VP2 proteins fused to EGFP assemble into fluorescent parvovirus-like particles. J Nanobiotechnology (2006) 0.83
A Brief Review of Computer-Assisted Approaches to Rational Design of Peptide Vaccines. Int J Mol Sci (2016) 0.78
Mapping Antigenic Epitopes on the Human Bocavirus Capsid. J Virol (2016) 0.77
Preparation, characterization and immunological evaluation: canine parvovirus synthetic peptide loaded PLGA nanoparticles. J Biomed Sci (2015) 0.76
Peptide-Recombinant VP6 Protein Based Enzyme Immunoassay for the Detection of Group A Rotaviruses in Multiple Host Species. PLoS One (2016) 0.75
Designing therapeutic cancer vaccines by mimicking viral infections. Cancer Immunol Immunother (2016) 0.75
Rapid evolution of RNA viruses. Annu Rev Microbiol (1987) 5.97
The autonomously replicating parvoviruses of vertebrates. Adv Virus Res (1987) 5.80
Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature (1982) 5.50
Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science (1990) 4.43
Chemically synthesized peptides predicted from the nucleotide sequence of the hepatitis B virus genome elicit antibodies reactive with the native envelope protein of Dane particles. Proc Natl Acad Sci U S A (1981) 4.26
The three-dimensional structure of canine parvovirus and its functional implications. Science (1991) 3.87
Protection of cattle against foot-and-mouth disease by a synthetic peptide. Science (1986) 2.62
Isolation and immunisation studies of a canine parco-like virus from dogs with haemorrhagic enteritis. Vet Rec (1979) 2.17
Structure, sequence, and function correlations among parvoviruses. Virology (1993) 2.06
Structure determination of feline panleukopenia virus empty particles. Proteins (1993) 1.99
HBTU activation for automated Fmoc solid-phase peptide synthesis. Pept Res (1992) 1.91
Hemagglutination by canine parvovirus: serologic studies and diagnostic applications. Am J Vet Res (1980) 1.83
Canine host range and a specific epitope map along with variant sequences in the capsid protein gene of canine parvovirus and related feline, mink, and raccoon parvoviruses. Virology (1988) 1.76
Nucleotide sequence and genome organization of canine parvovirus. J Virol (1988) 1.76
Evolution of the capsid protein genes of foot-and-mouth disease virus: antigenic variation without accumulation of amino acid substitutions over six decades. J Virol (1992) 1.72
Nucleotide sequence of the coat protein gene of canine parvovirus. J Virol (1985) 1.71
Emergence, natural history, and variation of canine, mink, and feline parvoviruses. Adv Virus Res (1990) 1.52
Genomic diversity and antigenic variation of HIV-1: links between pathogenesis, epidemiology and vaccine development. FASEB J (1991) 1.46
Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J Virol (1993) 1.45
Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization. J Immunol (1991) 1.39
Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences. Proc Natl Acad Sci U S A (1991) 1.37
Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J Virol (1990) 1.35
Canine parvovirus empty capsids produced by expression in a baculovirus vector: use in analysis of viral properties and immunization of dogs. J Gen Virol (1992) 1.34
Maternally derived immunity to canine parvovirus infection: transfer, decline, and interference with vaccination. J Am Vet Med Assoc (1982) 1.29
Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody. Gene (1992) 1.26
B-cell epitopes of canine parvovirus: distribution on the primary structure and exposure on the viral surface. J Virol (1993) 1.23
Rapid molecular evolution of wild type 3 poliovirus during infection in individual hosts. J Gen Virol (1990) 1.20
Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein. Virology (1991) 1.19
Fine mapping of canine parvovirus B cell epitopes. J Gen Virol (1991) 1.14
Recombinant vaccine for canine parvovirus in dogs. J Virol (1992) 1.11
Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis (1993) 1.10
Saponin adjuvants. 3. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in food-and-mouth disease vaccines. Arch Gesamte Virusforsch (1974) 1.09
Nucleotide sequence of feline panleukopenia virus: comparison with canine parvovirus identifies host-specific differences. J Gen Virol (1990) 1.09
Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity. Proc Natl Acad Sci U S A (1991) 1.08
The trypsin-sensitive RVER domain in the capsid proteins of minute virus of mice is required for efficient cell binding and viral infection but not for proteolytic processing in vivo. Virology (1992) 1.05
Synthetic peptides of the E2 glycoprotein of Venezuelan equine encephalomyelitis virus. II. Antibody to the amino terminus protects animals by limiting viral replication. Virology (1991) 1.05
Immunogenic peptide comprising a mouse hepatitis virus A59 B-cell epitope and an influenza virus T-cell epitope protects against lethal infection. J Virol (1990) 1.05
Experimental canine parvovirus infection in dogs. Cornell Vet (1982) 1.03
Identification of linear epitopes on Semliki Forest virus E2 membrane protein and their effectiveness as a synthetic peptide vaccine. J Gen Virol (1991) 1.00
A synthetic peptide derived from the amino acid sequence of canine parvovirus structural proteins which defines a B cell epitope and elicits antiviral antibody in BALB c mice. J Gen Virol (1990) 0.99
Studies on canine parvovirus infections: development of an inactivated vaccine. Am J Vet Res (1980) 0.94
Heterotypic protection induced by synthetic peptides corresponding to three serotypes of foot-and-mouth disease virus. J Virol (1990) 0.93
Marker vaccines, virus protein-specific antibody assays and the control of Aujeszky's disease. Vet Microbiol (1990) 0.92
Pathogenesis of canine parvovirus enteritis: sequential virus distribution and passive immunization studies. Vet Pathol (1985) 0.91
Production of porcine parvovirus empty capsids with high immunogenic activity. Vaccine (1992) 0.91
Neutralizing antibody to Mengo virus, induced by synthetic peptides. J Gen Virol (1991) 0.86
Topographical analysis of canine parvovirus virions and recombinant VP2 capsids. J Gen Virol (1993) 0.84
Virus neutralizing activity induced by synthetic peptides of glycoprotein D of herpes simplex virus type 1, selected by their reactivity with hyperimmune sera from mice. J Gen Virol (1990) 0.81
Isolation and characterization of the neutralizable epitope of simian retrovirus-1 (SRV-1) and of the cell receptor for the virus. Adv Exp Med Biol (1991) 0.80
Immunogenicity of peptides simulating a neutralization epitope of transmissible gastroenteritis virus. Virology (1991) 0.80
Bovine herpesvirus-1 (infectious bovine rhinotracheitis virus)-based viral vector which expresses foot-and-mouth disease epitopes. Vaccine (1991) 0.79
Evaluation of enzyme-linked immunosorbent assays based on monoclonal antibodies for the serology and antigen detection in canine parvovirus infections. Vet Q (1990) 0.79
[Protection from foot-and-mouth disease virus in naturally-susceptible animals by a linear polymer of a synthetic peptide]. Bioorg Khim (1991) 0.77
A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med (2001) 16.32
Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet (1998) 16.30
Emerging marine diseases--climate links and anthropogenic factors. Science (1999) 10.22
A pandemic warning? Nature (1997) 8.70
Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill (2012) 7.96
Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc Natl Acad Sci U S A (1984) 7.77
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med (1995) 7.26
Detection of influenza A viruses from different species by PCR amplification of conserved sequences in the matrix gene. J Clin Microbiol (2000) 6.96
Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A (1988) 6.74
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med (1997) 6.23
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet (2000) 5.03
Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill (2012) 4.95
Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol (2001) 4.90
Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods (1998) 3.67
Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci U S A (1991) 3.15
Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill (2013) 2.97
Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol (1997) 2.86
Molecular cloning and nucleotide sequence of hog cholera virus strain Brescia and mapping of the genomic region encoding envelope protein E1. Virology (1990) 2.59
Characterization of proteins encoded by ORFs 2 to 7 of Lelystad virus. Virology (1995) 2.33
Immunohistochemical detection of prion protein in lymphoid tissues of sheep with natural scrapie. J Clin Microbiol (1996) 2.26
Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J Virol (2000) 2.25
Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein. Proc Natl Acad Sci U S A (1985) 2.23
Evaluation of six immunoassays for detection of dengue virus-specific immunoglobulin M and G antibodies. Clin Diagn Lab Immunol (2000) 2.21
Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell (1989) 2.20
Human influenza virus A/HongKong/156/97 (H5N1) infection. Vaccine (1998) 2.17
Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol (2000) 2.11
Haemorrhagic fever with renal syndrome. Lancet (1993) 2.09
Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol (1997) 2.07
Control of severe hyperparathyroidism and regression of a brown tumour after treatment with i.v. alfacalcidol in a uraemic patient. Nephrol Dial Transplant (1995) 2.07
Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol (2000) 2.07
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine (2001) 2.06
Canine distemper virus from diseased large felids: biological properties and phylogenetic relationships. J Gen Virol (1996) 2.06
An epitope shared by the hemagglutinins of H1, H2, H5, and H6 subtypes of influenza A virus. Acta Virol (1999) 2.06
Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med (1999) 2.01
The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 2.00
Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol (2000) 1.95
Influenza types and patient population. Lancet (1995) 1.94
Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature (1984) 1.90
Measles in a Dutch hospital introduced by an immuno-compromised infant from Indonesia infected with a new virus genotype. Lancet (2000) 1.87
Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant (2007) 1.83
Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. J Clin Microbiol (2001) 1.70
Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition. AIDS (1988) 1.68
Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother (2000) 1.66
Viral replication and development of specific immunity in macaques after infection with different measles virus strains. J Infect Dis (1994) 1.65
Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region. Arch Virol (2000) 1.61
Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J Gen Virol (1997) 1.61
Identification of virus causing recent seal deaths. Nature (1988) 1.58
A study of the cross-reacting antigens on the intact foot-and-mouth disease virus and its 12S Subunits with antisera against the structural proteins. J Gen Virol (1980) 1.57
Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine (1996) 1.55
Prevalence and association between herpes simplex virus types 1 and 2-specific antibodies in attendees at a sexually transmitted disease clinic. Int J Epidemiol (2001) 1.53
Immunohistochemical detection and localization of prion protein in brain tissue of sheep with natural scrapie. Vet Pathol (1995) 1.52
Residues involved in the antigenic sites of transmissible gastroenteritis coronavirus S glycoprotein. Virology (1991) 1.51
PCBs are a health risk for humans and wildlife. Science (2000) 1.51
Influenza virus: a master of metamorphosis. J Infect (2000) 1.50
Localisation of Nramp1 in macrophages: modulation with activation and infection. J Cell Sci (1998) 1.50
Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation. J Virol (1993) 1.50
The hanta hunting study: underdiagnosis of Puumala hantavirus infections in symptomatic non-travelling leptospirosis-suspected patients in the Netherlands, in 2010 and April to November 2011. Euro Surveill (2014) 1.49
Canine distemper virus--a morbillivirus in search of new hosts? Trends Microbiol (1997) 1.49
Recommendations for the use of inactivated influenza vaccines and other preventive measures. Vaccine (2001) 1.47
Mass die-Off of Caspian seals caused by canine distemper virus. Emerg Infect Dis (2001) 1.46
[Treatment and outcome of pneumococcal meningitis in adults. Study of a recent series of 70 episodes]. Med Clin (Barc) (1995) 1.43
[Influenza pandemics: past and future]. Ned Tijdschr Geneeskd (1999) 1.42
Herpes simplex virus type 1 (HSV-1)--induced retinitis following herpes simplex encephalitis: indications for brain-to-eye transmission of HSV-1. Ann Neurol (2000) 1.42
Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis (1998) 1.42
Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol (2000) 1.39
Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro. J Virol (1998) 1.39
Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol (2001) 1.38
Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand J Immunol (1995) 1.38
Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1. Arch Virol (1992) 1.37
Monoclonal antibodies to polioviruses. Comparison of intratypic strain differentiation of poliovirus type 1 using monoclonal antibodies versus cross-absorbed antisera. Intervirology (1983) 1.35
Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J Virol (1990) 1.35
Characterization of fastidious adenovirus types 40 and 41 by DNA restriction enzyme analysis and by neutralizing monoclonal antibodies. Virus Res (1989) 1.34
An ELISA for detection of antibodies against influenza A nucleoprotein in humans and various animal species. Arch Virol (1990) 1.34
Combination of reverse transcriptase PCR analysis and immunoglobulin M detection on filter paper blood samples allows diagnostic and epidemiological studies of measles. J Clin Microbiol (2001) 1.34
Detection, typing, and subtyping of enteric adenoviruses 40 and 41 from fecal samples and observation of changing incidences of infections with these types and subtypes. J Clin Microbiol (1993) 1.31
Antigenic and genetic characterization of swine influenza A (H1N1) viruses isolated from pneumonia patients in The Netherlands. Virology (2001) 1.30
Measles virus-specific human T cell clones. Characterization of specificity and function of CD4+ helper/cytotoxic and CD8+ cytotoxic T cell clones. J Immunol (1989) 1.29
Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J Infect Dis (1997) 1.29
New clues to the emergence of flu pandemics. Nat Med (1998) 1.28
ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine (1999) 1.28
Development of a real-time quantitative RT-PCR for the detection of HIV-2 RNA in plasma. J Virol Methods (2000) 1.28
Functional analysis of DR17(DR3)-restricted mycobacterial T cell epitopes reveals DR17-binding motif and enables the design of allele-specific competitor peptides. J Immunol (1992) 1.27
Plant-derived vaccine protects target animals against a viral disease. Nat Biotechnol (1997) 1.27
Antigen loading of MHC class I molecules in the endocytic tract. Traffic (2001) 1.27
A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine (2000) 1.26
Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS (1998) 1.24
Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J Med Virol (1997) 1.24
Porcine parvovirus: DNA sequence and genome organization. J Gen Virol (1989) 1.24
Monoclonal antibodies to polioviruses. Production of specific monoclonal antibodies to the Sabin vaccine strains. Intervirology (1981) 1.23
B-cell epitopes of canine parvovirus: distribution on the primary structure and exposure on the viral surface. J Virol (1993) 1.23